This mechanism has been verified in alcoholic liver disease and nonalcoholic fatty liver disease.[10,11] On the other hand, short-chain fatty acids regulate the PPAR-α pathway through the GPR41/43 receptor and inhibit lipid synthesis mediated by SREBP1. Here, FFAR3 is linked to metabolic dysfunction-associated steatotic liver disease.